Understand the research.

Researchers reviewed documented conversations about care goals for adolescents and young adults with cancer. Discussions often occurred late, highlighting opportunities to improve communication about patients’ priorities earlier in care.

Researchers examined how mesenchymal stem cells in people at increased ovarian-cancer risk may support formation of early lesions in fallopian-tube tissue. The findings explore disease biology and possible prevention targets.

NCI reports FDA authorization of nivolumab with ipilimumab as initial treatment for advanced colorectal cancer with MSI-high or deficient mismatch repair features. The article reviews the supporting trial and patient population.

An experimental device measures how firmly cancer cells attach to surfaces. Researchers investigated whether this property could help identify cells with greater potential to spread; clinical usefulness needs further study.

Scientists tested a rapid method for detecting tumor-associated genetic changes during brain surgery. The work explores how faster molecular information might help surgeons distinguish tumor from surrounding tissue.

Researchers are investigating increasing diagnoses of several cancers before age 50, including colorectal and breast cancer. NCI describes questions about environmental exposures, inherited risk and the support needs of younger adults.

A study examined pancreatic imaging surveillance in people at elevated risk. Earlier detection and survival findings support further evaluation, while the approach and eligibility differ from screening the general population.

Two trials investigated adding JAK inhibitors to immune checkpoint treatment to address persistent inflammation. NCI explains the preliminary findings and why larger studies are needed before drawing broad conclusions.

Two mouse studies examined chemotherapy with the experimental KRAS inhibitor MRTX1133. The combinations reduced tumor growth and spread more than the individual treatments in these models; patient benefit requires clinical testing.

Researchers engineered cancer cells with drug-controlled genetic switches, aiming to redirect treatment resistance. Experiments in mouse lung-cancer models were promising, but delivery and effectiveness in people remain unresolved.

Researchers developed an AI model using routine blood tests and medical information to study responses to immune checkpoint inhibitors. NCI describes its evaluation and remaining questions. This research model is not a personal treatment recommendation or a tool offered by OncologyBridge.

A small early trial of GD2-directed CAR T cells showed tumor shrinkage in some children and young adults with diffuse midline gliomas. NCI describes the experimental approach, safety considerations and need for larger studies.